Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolmetin-induced hemolysis.

J E Squires, P D Mintz, S Clark

    Transfusion
    |September 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    This case study details drug-associated immune hemolysis caused by tolmetin, a nonsteroidal anti-inflammatory medication. Discontinuation of tolmetin resolved the patient's hemolytic anemia, highlighting the drug's role.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Indocyanine green clearance's association with liver function in paediatric liver disease.

    Acta paediatrica (Oslo, Norway : 1992)·2024
    Same author

    Exploring reasons for overuse of contralateral prophylactic mastectomy in Canada.

    Current oncology (Toronto, Ont.)·2019
    Same author

    Patient decision aid for contralateral prophylactic mastectomy for use in the consultation: a feasibility study.

    Current oncology (Toronto, Ont.)·2019
    Same author

    Clotting Factor (Cf) Product Use And Same-Day Risk For Thrombotic Adverse Events (Tes), As Recorded In Large Health Care Database During 2008-2013 Study Period.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
    Same author

    Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008-2013.

    Journal of thrombosis and haemostasis : JTH·2015
    Same author

    Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012.

    Vox sanguinis·2014
    Same journal

    Investigation of the preanalytical stability of blood donor samples.

    Transfusion·2026
    Same journal

    The need for dried plasma-Still a national issue: Where are we and recommendations.

    Transfusion·2026
    Same journal

    Spray dried plasma manufactured from apheresis and whole blood derived plasma.

    Transfusion·2026
    Same journal

    Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

    Transfusion·2026
    Same journal

    AABB survey on directed blood donation practices.

    Transfusion·2026
    Same journal

    Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

    Transfusion·2026
    See all related articles

    Area of Science:

    • Immunology
    • Hematology
    • Pharmacology

    Background:

    • Immune hemolytic anemia can be triggered by various medications.
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause adverse hematologic effects.
    • Tolmetin is an NSAID used for managing arthritic pain.

    Observation:

    • A patient presented with symptoms suggestive of hemolytic anemia while on tolmetin therapy.
    • Serologic tests revealed a positive direct antiglobulin test in the absence of tolmetin.
    • Red blood cell eluates showed panagglutination, indicating antibody presence.

    Findings:

    • Tolmetin-dependent antibodies were identified in the patient's serum.
    • These antibodies caused agglutination only in the presence of tolmetin.

    Related Experiment Videos

  • Discontinuing tolmetin led to the resolution of hemolytic anemia, jaundice, and bilirubinuria within three months.

    • Implications:

    • This case reinforces the association between NSAIDs, specifically tolmetin, and drug-induced immune hemolytic anemia.
    • It underscores the importance of considering drug-induced immune hemolysis in patients presenting with unexplained anemia.
    • The findings are comparable to previously reported cases involving zomepirac, another NSAID, suggesting a class effect.